AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO EVALUATE PATRITUMAB DERUXTECAN MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN HORMONE RECEPTORPOSITIVE, HER2-NEGATIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (HERTHENA-BREAST04)

Registry ID

MK-1022-016

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2026-05-07

Last update

2025-07-17

Conditions

• HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED UNRESECTABLE BRCA ASSOCIATED BREAST CANCER

Related clinical trials

• AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF MK-2870 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN¿S CHOICE IN PARTICIPANTS WITH HR+/HER2 UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY (TROPION BREAST01)
• XENERA-1: A MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED PHASE II TRIAL TO COMPARE EFFICACY OF XENTUZUMAB IN COMBINATION WITH EVEROLIMUS AND EXEMESTANE VERSUS EVEROLIMUS AND EXEMESTANE IN POST-MENOPAUSAL WOMEN WITH HR+ / HER2-METASTATIC BREAST CANCER AND NON-VISCERAL DISEASE
• A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY

View on source registry